Table 1. Published studies of EGFR-targeted therapy for penile squamous cell carcinoma.
| Authors | Treatment | N | Number of response |
|---|---|---|---|
| Carthon et al., 2014 (34) | Cetuximab | 5 | 1 (20%) |
| Cetuximab + cisplatin/carboplatin | 12 | 4 (33%) | |
| Cetuximab + TIP | 3 | 3 (100%) | |
| Erlotinib | 2 | 0 | |
| Gefitinib | 1 | 0 | |
| Rescigno et al., 2012 (35) | Cetuximab + docetaxel | 1 | 1 |
| Pandey et al., 2013 (36) | Nimotuzumab + paclitaxel | 1 | 1 |
| Men et al., 2014 (37) | Nimotuzumab + paclitaxel + cisplatin | 1 | 1 |
| Necchi et al., 2011 (38) | Panitumumab | 1 | 1 |
| Brown et al., 2014 (39) | Cetuximab | 1 | 0 |
| Panitumumab | 1 | 1 | |
| Panitumumab + cisplatin | 1 | 1 |
TIP, paclitaxel, ifosfamide, and cisplatin.